Literature DB >> 9597564

Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure.

R F Frye1, A Adedoyin, K Mauro, G R Matzke, R A Branch.   

Abstract

Chlorzoxazone is being developed and proposed for use as a probe to measure in vivo cytochrome P4502E1 activity, but the phenotypic trait measures that are used vary. Although the doses proposed for phenotyping range from 250 mg to 750 mg, the effect of dose on chlorzoxazone hydroxylation has not previously been evaluated. The purpose of this study was to characterize the pharmacokinetics of chlorzoxazone in normal healthy volunteers (N = 6) after single randomized oral doses of 250 mg and 750 mg. An additional 10 volunteers underwent a detailed pharmacokinetic study using the 250-mg dose to further evaluate proposed phenotypic trait measures (N = 16). Timed blood and urine samples were obtained for 10 hours for chlorzoxazone and 6-hydroxychlorzoxazone determination by HPLC. Pharmacokinetic parameter estimates were estimated using noncompartmental methods. Evaluation of phenotypic trait measures show that 6-hydroxychlorzoxazone to chlorzoxazone plasma concentration ratios at 2 to 4 hours after drug administration demonstrated the highest correlations with metabolite formation clearance (r = 0.9; P < 0.001). Urine-based parameters (e.g., total recovery) were not significantly related to formation clearance (r = 0.5; P > 0.05). Dose dependency in chlorzoxazone metabolism was shown by a 30% increase (P < 0.05) in the dose-normalized area under the concentration-time curve (AUC) of chlorzoxazone and lower incremental dose-normalized urinary recovery of 6-hydroxychlorzoxazone at early timepoints after the 750-mg dose. In addition, the plasma ratio of 6-hydroxychlorzoxazone to chlorzoxazone at 4 hours was reduced by 48% in 5 of 6 subjects after the 750-mg dose (P > 0.05). These data suggest that 6-hydroxylation was saturated at the higher dose and illustrate the importance of dose selection in phenotyping. The results of this study indicate that a chlorzoxazone dose of 250 mg should be used and that a single plasma ratio obtained 2 to 4 hours after dosing is reflective of chlorzoxazone 6-hydroxylation and thus may serve as a cytochrome P4502E1 phenotypic trait measure.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9597564     DOI: 10.1002/j.1552-4604.1998.tb04381.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

1.  Comparison of chlorzoxazone one-sample methods to estimate CYP2E1 activity in humans.

Authors:  Iza Kramer; Kim Dalhoff; Jens O Clemmesen; Steffen Loft; Henrik E Poulsen
Journal:  Eur J Clin Pharmacol       Date:  2003-11-11       Impact factor: 2.953

2.  Modification of CYP2E1 and CYP3A4 activities in haemoglobin E-beta thalassemia patients.

Authors:  Nuntiya Somparn; Upa Kukongviriyapan; Wichittra Tassaneeyakul; Arunee Jetsrisuparb; Veerapol Kukongviriyapan
Journal:  Eur J Clin Pharmacol       Date:  2006-11-21       Impact factor: 2.953

3.  Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses.

Authors:  Nicolas Hohmann; Antje Blank; Jürgen Burhenne; Yosuke Suzuki; Gerd Mikus; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2019-08-09       Impact factor: 4.335

4.  Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity.

Authors:  N K Zgheib; R F Frye; T S Tracy; M Romkes; R A Branch
Journal:  Br J Clin Pharmacol       Date:  2006-10-19       Impact factor: 4.335

5.  Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.

Authors:  Reginald F Frye; Robert A Branch
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

6.  Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity.

Authors:  Lena Ernstgård; Margareta Warholm; Gunnar Johanson
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

7.  A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study.

Authors:  Ashish Sharma; Sylvie Pilote; Pierre M Bélanger; Marie Arsenault; Bettina A Hamelin
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

8.  Evaluation of capacity-limited first-pass effect through liver by three-points sampling in portal and hepatic veins and systemic artery.

Authors:  Shinya Ueda; Kiyoshi Yamaoka; Jyoji Yui; Akio Shigematsu; Terumichi Nakagawa
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

9.  Exogenous and endogenous determinants of blood trihalomethane levels after showering.

Authors:  Lorraine C Backer; Qing Lan; Benjamin C Blount; J R Nuckols; Robert Branch; Christopher W Lyu; Stephanie M Kieszak; Marielle C Brinkman; Sydney M Gordon; W Dana Flanders; Marjorie Romkes; Kenneth P Cantor
Journal:  Environ Health Perspect       Date:  2008-01       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.